BOLD (Boundless Bio) Debt-to-Equity : 0.32 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Debt-to-Equity?

Boundless Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Boundless Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $47.63 Mil. Boundless Bio's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $150.64 Mil. Boundless Bio's debt to equity for the quarter that ended in Dec. 2024 was 0.32.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Boundless Bio's Debt-to-Equity or its related term are showing as below:

BOLD' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: -0.01 Max: 0.32
Current: 0.32

During the past 4 years, the highest Debt-to-Equity Ratio of Boundless Bio was 0.32. The lowest was -0.06. And the median was -0.01.

BOLD's Debt-to-Equity is ranked worse than
65.68% of 1017 companies
in the Biotechnology industry
Industry Median: 0.14 vs BOLD: 0.32

Boundless Bio Debt-to-Equity Historical Data

The historical data trend for Boundless Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Debt-to-Equity Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

-0.01

-0.06

-0.02

0.32

Boundless Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial						-0.02	-0.01	0.01	-	0.32

Competitive Comparison of Boundless Bio's Debt-to-Equity

For the Biotechnology subindustry, Boundless Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Boundless Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Boundless Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	47.632)	/	150.642
	=	0.32

Boundless Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	47.632)	/	150.642
	=	0.32

Boundless Bio (NAS:BOLD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Boundless Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.